







My doctor sent over some information about treatment.If you get COVID and you are high risk talk to your doctor ASAP for prescription meds.Here’s a list of OTC meds One Medical recommends for fighting off COVID symptoms if you aren’t high risk and when to seek further help. pic.twitter.com/e8fGR5Llte— Sasha Perigo (@sashaperigo) May 19, 2022
COVID survivors at increased risk of long-term gastrointestinal conditions
Although people with severe COVID had highest risk, mild cases also upped risks.

Long COVID management: a mini review of current recommendations and underutilized modalities
Long COVID is a condition that develops in a subset of patients after COVID-19 infection comprising of symptoms of varying severity encompassing multiple organ systems. Currently, long COVID is without consensus on a formal definition, identifiable biomarkers, and validated treatment. Long COVID is expected to be a long-term chronic condition for a subset of patients and is associated with suffering and incapacity. There is an urgent need for clear management guidelines for the primary care provider, who is essential in bridging the gap with more specialized care to improve quality of life and functionality in their patients living with long COVID. The purpose of this mini review is to provide primary care providers with the latest highlights from existing literature regarding the most common long COVID symptoms and current management recommendations. This review also highlights the underutilized interventions of stellate ganglion blocks and low-dose naltrexone, both with well-established safety profiles demonstrated to improve quality of life and functionality for patients suffering with some symptoms of long COVID, and encourages prompt referral to interventional pain management.

Underlying Conditions and the Higher Risk for Severe COVID-19
Learn risk factors for severe outcomes from COVID-19 and actions to take.
Long Covid Studies - Possible long COVID treatments
See all researched treatments for long COVID, along with evidence summaries.
You've Got COVID! Minimize Your Symptoms and Reduce Your Long COVID Risk
Essential guidance for managing acute COVID-19 to minimize symptoms and reduce Long COVID risk. Learn what to do when you test positive.

Vaccination Dramatically Lowers Long COVID Risk
Several new studies reveal that getting multiple COVID vaccine doses provides strong protection against lingering symptoms

Timing of Long COVID Improvement in Prospectively Followed RECOVER-Adult Participants
Background: Long COVID (LC) is widespread; however, limited information has been reported on the likelihood that symptoms remit over time. Objective: To evaluate the likelihood of improvement among persons with likely LC. Design: Prospective, multisite cohort study (RECOVER-Adult [Researching COVID to Enhance Recovery]). Setting: 83 U.S.-based sites across 33 states; Washington, DC; and Puerto Rico. Participants: 1019 persons in RECOVER-Adult with likely LC (LC Research Index [LCRI] ≥11) 12 months after first SARS-CoV-2 infection. Measurements: The primary outcome was time until 2 consecutive study visits with LCRI less than 11. Secondary outcomes were time until LCRI measure reduced 50% or more and quality of life was good or better, and LCRI decreased to 0. Unadjusted estimates of cumulative incidence and adjusted marginal cumulative incidence by age, sex, SARS-CoV-2 wave, and LC subtype were reported across all follow-up time points. Results: An estimated 36.2% (95% CI, 33.0% to 39.5%) met the primary outcome by 24 months after infection, and 50.1% (CI, 46.1% to 54.0%) met the primary outcome by 36 months. An estimated 56.4% (CI, 52.2% to 60.4%) and 26.9% (CI, 23.3% to 30.5%), respectively, met the 2 secondary outcomes by 36 months. Among persons who still reported likely LC at 18 months and 24 months after first infection, relative timing of subsequent symptom improvement was similar. Limitation: Findings in this observational cohort are interpretable in a population with prevalent likely LC and do not address causal relationships between individual characteristics and symptom improvement. Conclusion: Among persons with likely LC 12 months after initial SARS-CoV-2 infection, one half experience meaningful reductions in symptoms by 36 months, whereas a quarter experience complete remission of symptoms. These findings underscore both the potential for natural recovery and the urgent need for placebo-controlled therapeutic intervention trials. Primary Funding Source: National Institutes of Health.

Timing of Long COVID Improvement in Prospectively Followed RECOVER-Adult Participants
Background: Long COVID (LC) is widespread; however, limited information has been reported on the likelihood that symptoms remit over time. Objective: To evaluate the likelihood of improvement among persons with likely LC. Design: Prospective, multisite cohort study (RECOVER-Adult [Researching COVID to Enhance Recovery]). Setting: 83 U.S.-based sites across 33 states; Washington, DC; and Puerto Rico. Participants: 1019 persons in RECOVER-Adult with likely LC (LC Research Index [LCRI] ≥11) 12 months after first SARS-CoV-2 infection. Measurements: The primary outcome was time until 2 consecutive study visits with LCRI less than 11. Secondary outcomes were time until LCRI measure reduced 50% or more and quality of life was good or better, and LCRI decreased to 0. Unadjusted estimates of cumulative incidence and adjusted marginal cumulative incidence by age, sex, SARS-CoV-2 wave, and LC subtype were reported across all follow-up time points. Results: An estimated 36.2% (95% CI, 33.0% to 39.5%) met the primary outcome by 24 months after infection, and 50.1% (CI, 46.1% to 54.0%) met the primary outcome by 36 months. An estimated 56.4% (CI, 52.2% to 60.4%) and 26.9% (CI, 23.3% to 30.5%), respectively, met the 2 secondary outcomes by 36 months. Among persons who still reported likely LC at 18 months and 24 months after first infection, relative timing of subsequent symptom improvement was similar. Limitation: Findings in this observational cohort are interpretable in a population with prevalent likely LC and do not address causal relationships between individual characteristics and symptom improvement. Conclusion: Among persons with likely LC 12 months after initial SARS-CoV-2 infection, one half experience meaningful reductions in symptoms by 36 months, whereas a quarter experience complete remission of symptoms. These findings underscore both the potential for natural recovery and the urgent need for placebo-controlled therapeutic intervention trials. Primary Funding Source: National Institutes of Health.

Patient-reported treatment outcomes in ME/CFS and long COVID
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and long COVID are persistent multisystem illnesses affecting many patients. With no known effective FDA-approved treatments for either condition, patient-reported outcomes of treatments may prove helpful in identifying management strategies that can improve patient care and generate new avenues for research. Here, we present the results of an ME/CFS and long COVID treatment survey with responses from 3,925 patients. We assess the experiences of these patients with more than 150 treatments in conjunction with their demographics, symptoms, and comorbidities. Treatments with the greatest perceived benefits are identified. Patients with each condition who participated in the study shared similar symptom profiles, including all the core symptoms of ME/CFS, e.g., 89.7% of ME/CFS and 79.4% of long COVID reported postexertional malaise (PEM). Furthermore, treatment responses between these two patient groups were significantly correlated (R 2 = 0.68). Patient subgroups, characterized by distinct symptom profiles and comorbidities, exhibited increased responses to specific treatments, e.g., a POTS-dominant cluster benefiting from autonomic modulators and a cognitive-dysfunction cluster from CNS stimulants. This study underscores the symptomatic and therapeutic similarities between ME/CFS and long COVID and highlights the commonalities and nuanced complexities of infection-associated chronic diseases and related conditions. While this study does not provide recommendations for specific therapies, in the absence of approved treatments, insights from patient-reported experiences provide urgently needed real-world evidence for developing targeted patient care therapies and future clinical trials.

Long COVID still has no cure — so these patients are turning to research
With key long COVID trials yet to yield results, people with the condition are trying to change how clinical trials are done.

What Are COVID-19’s Long-Term Medical Effects?
Fascinating email from TPM Reader JO, whose personal bio is tailor-made for...

New research shows younger and middle-aged adults have worse long COVID symptoms than older adults
New study from Northwestern Medicine finds symptoms occurred regardless of mild or severe COVID-19 infection

Mixing Covid jabs has good immune response, study finds
Any combination of Pfizer or AstraZeneca for first and second doses works, a study suggests.

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Essentials of Diagnosis and Management
Despite myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) affecting millions of people worldwide, many clinicians lack the knowledge to appropriately diagnose or manage ME/CFS. Unfortunately, clinical guidance has been scarce, obsolete, or potentially harmful. Consequently, up to 91% of patients in the United States remain undiagnosed, and those diagnosed often receive inappropriate treatment. These problems are of increasing importance because after acute COVID-19, a significant percentage of people remain ill for many months with an illness similar to ME/CFS.

OTC nasal spray reduces the risk of COVID-19 infection by 70%
The active ingredient in a common over-the-counter allergy spray may do more than ease hay fever symptoms. A new clinical trial found azelastine cut COVID-19 infections by 70%, hinting at a cheap, accessible way to add protection alongside vaccines.

Can addressing gut issues treat long COVID in children?
Study hopes to answer questions about connection between GI and neurological symptoms.
